Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1617srh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload

NEWS EXPRESS	April 18 CURRENT WINDOWS VERSION IS V6.0, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:55:14 ON 17 MAY 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 10:55:46 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6
DICTIONARY FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> BPD-MA/cn
BPD-MA IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s BPD-MA/cn
L1 1 BPD-MA/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 129497-78-5 REGISTRY
CN 23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, (4R,4aS)-rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-
OTHER NAMES:
CN (.+-.)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester mixt. with (.+-.)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester
CN **BPD-MA**
CN CL 318952
CN Verteporfin
FS STEREOSEARCH
DR 121987-00-6, 129162-83-0, 136415-38-8
MF C41 H42 N4 O8
CI IDS
SR CA
LC STN Files: ADISINSIGHT, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CEN,
CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, MEDLINE, MRCK*, PHAR, PROMT, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

CM 1

CRN 121310-58-5
CMF C40 H40 N4 O8

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 67-56-1
CMF C H4 O

H3C—OH

145 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s A-EA6/cn
L2 0 A-EA6/CN

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.51	12.66

FILE 'STNGUIDE' ENTERED AT 11:02:22 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2001 (20010511/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	12.66

FILE 'REGISTRY' ENTERED AT 11:10:12 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6
DICTIONARY FILE UPDATES: 16 MAY 2001 HIGHEST RN 336099-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

```
=> s porphyrin/cn
L3            1 PORPHYRIN/CN

=> s porphyrin
           2983 PORPHYRIN
              2 PORPHYRINS
L4         2983 PORPHYRIN
                  (PORPHYRIN OR PORPHYRINS)

=> s porfimer/cn
L5            0 PORFIMER/CN

=> s porfimer
L6            1 PORFIMER

=> d

L6   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN   87806-31-3  REGISTRY
CN   Photofrin Porfimer sodium (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   CL 184116
CN   DHE
CN   Photofrin 2
CN   Photofrin II
CN   Porfimer sodium
CN   PPS
MF   Unspecified
CI   MAN
LC   STN Files:   ADISINSIGHT, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA,
       CAPLUS, CBNB, CEN, CIN, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
       DRUGUPDATES, IPA, MRCK*, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USAN,
       USPATFULL
         (*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
             466 REFERENCES IN FILE CA (1967 TO DATE)
              15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             466 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> fil stng
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              17.32      29.98

FILE 'STNGUIDE' ENTERED AT 11:11:26 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
```

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2001 (20010511/UP).

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	29.98

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 11:15:02 ON 17 MAY 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s l1 or (L 318952) or Verteporfin
```
         11*  FILE ADISALERTS
          3   FILE ADISINSIGHT
          0*  FILE AQUASCI
          3   FILE BIOBUSINESS
          3*  FILE BIOCOMMERCE
         76   FILE BIOSIS
  10 FILES SEARCHED...
          8   FILE BIOTECHNO
          1*  FILE CABA
        132   FILE CANCERLIT
         66*  FILE CAPLUS
          1*  FILE CEABA-VTB
          1   FILE CEN
         32   FILE CIN
          1*  FILE CONFSCI
          0*  FILE CROPB
          0*  FILE CROPU
  20 FILES SEARCHED...
          0*  FILE DDFB
         36*  FILE DDFU
          0*  FILE DGENE
          0*  FILE DRUGB
         13   FILE DRUGLAUNCH
          9   FILE DRUGMONOG2
         39   FILE DRUGNL
         36*  FILE DRUGU
          1   FILE DRUGUPDATES
          4*  FILE EMBAL
         70   FILE EMBASE
         23*  FILE ESBIOBASE
          0*  FILE FOMAD
          0*  FILE FOREGE
          0*  FILE FROSTI
          0*  FILE GENBANK
          0*  FILE HEALSAFE
          0*  FILE IFIPAT
          0*  FILE KOSMET
```

```
          9*  FILE LIFESCI
          0*  FILE MEDICONF
        148   FILE MEDLINE
  44 FILES SEARCHED...
          0*  FILE NTIS
          0*  FILE OCEAN
         43*  FILE PASCAL
          1   FILE PHAR
          5*  FILE PHIC
         79*  FILE PHIN
        196   FILE PROMT
         85*  FILE SCISEARCH
         32   FILE TOXLINE
         38   FILE TOXLIT
         11*  FILE USPATFULL
          2   FILE WPIDS
          2   FILE WPINDEX

  35 FILES HAVE ONE OR MORE ANSWERS,   59 FILES SEARCHED IN STNINDEX

L7   QUE L1 OR (L 318952) OR VERTEPORFIN

=> s restenos? or restrict? or (intimal hyperplas?) or narrow?
       5038   FILE ADISALERTS
        344   FILE ADISINSIGHT
      24271   FILE AGRICOLA
       2216   FILE ANABSTR
      19791   FILE AQUASCI
      12390   FILE BIOBUSINESS
        997   FILE BIOCOMMERCE
     231140   FILE BIOSIS
      12776   FILE BIOTECHABS
      12776   FILE BIOTECHDS
      79618   FILE BIOTECHNO
      80189   FILE CABA
      45805   FILE CANCERLIT
     288989   FILE CAPLUS
       4253   FILE CEABA-VTB
       1598   FILE CEN
       9004   FILE CIN
       4076   FILE CONFSCI
        512   FILE CROPB
       2079   FILE CROPU
  20 FILES SEARCHED...
       1081   FILE DDFB
       6537   FILE DDFU
      60159   FILE DGENE
       1081   FILE DRUGB
        426   FILE DRUGLAUNCH
          2   FILE DRUGMONOG2
        362   FILE DRUGNL
      13072   FILE DRUGU
        287   FILE DRUGUPDATES
       1943   FILE EMBAL
     192382   FILE EMBASE
      63621   FILE ESBIOBASE
        244   FILE FOMAD
        698   FILE FOREGE
       3119   FILE FROSTI
       6524   FILE FSTA
```

```
    195972   FILE GENBANK
      2064   FILE HEALSAFE
    136591   FILE IFIPAT
  39 FILES SEARCHED...
     38964   FILE JICST-EPLUS
       299   FILE KOSMET
     76071   FILE LIFESCI
       149   FILE MEDICONF
    228280   FILE MEDLINE
      3305   FILE NIOSHTIC
     34472   FILE NTIS
      7498   FILE OCEAN
    124528   FILE PASCAL
       262   FILE PHAR
        81   FILE PHIC
     12271   FILE PHIN
    228071   FILE PROMT
    229359   FILE SCISEARCH
        15   FILE SYNTHLINE
     37856   FILE TOXLINE
     53346   FILE TOXLIT
  56 FILES SEARCHED...
    762478   FILE USPATFULL
    180497   FILE WPIDS
    180497   FILE WPINDEX

  59 FILES HAVE ONE OR MORE ANSWERS,   59 FILES SEARCHED IN STNINDEX

L8   QUE RESTENOS? OR RESTRICT? OR (INTIMAL HYPERPLAS?) OR NARROW?

=> s l7 and l8
          0*  FILE ADISALERTS
          1   FILE ADISINSIGHT
          0*  FILE AQUASCI
          0*  FILE BIOCOMMERCE
          0*  FILE CABA
          4   FILE CANCERLIT
          5*  FILE CAPLUS
          0*  FILE CEABA-VTB
          0*  FILE CONFSCI
          0*  FILE CROPB
          0*  FILE CROPU
          0*  FILE DDFB
          1*  FILE DDFU
          0*  FILE DGENE
          0*  FILE DRUGB
  26 FILES SEARCHED...
          1   FILE DRUGNL
          1*  FILE DRUGU
          1   FILE DRUGUPDATES
          0*  FILE EMBAL
          3   FILE EMBASE
          0*  FILE ESBIOBASE
          0*  FILE FOMAD
          0*  FILE FOREGE
          0*  FILE FROSTI
          0*  FILE GENBANK
          0*  FILE HEALSAFE
          0*  FILE IFIPAT
          0*  FILE KOSMET
```

```
          0*  FILE LIFESCI
          0*  FILE MEDICONF
          7   FILE MEDLINE
          0*  FILE NTIS
          0*  FILE OCEAN
          1*  FILE PASCAL
  48 FILES SEARCHED...
          1   FILE PHAR
          0*  FILE PHIC
          5*  FILE PHIN
          5   FILE PROMT
          2*  FILE SCISEARCH
          2   FILE TOXLINE
          9*  FILE USPATFULL
          1   FILE WPIDS
          1   FILE WPINDEX

  18 FILES HAVE ONE OR MORE ANSWERS,    59 FILES SEARCHED IN STNINDEX

L9   QUE L7 AND L8

=> d rank
F1            9*  USPATFULL
F2            7   MEDLINE
F3            5   PROMT
F4            5*  CAPLUS
F5            5*  PHIN
F6            4   CANCERLIT
F7            3   EMBASE
F8            2   TOXLINE
F9            2*  SCISEARCH
F10           1   ADISINSIGHT
F11           1   DRUGNL
F12           1   DRUGUPDATES
F13           1   PHAR
F14           1   WPIDS
F15           1   WPINDEX
F16           1*  DDFU
F17           1*  DRUGU
F18           1*  PASCAL


=> file f1-f18
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               6.75      36.73

FILE 'USPATFULL' ENTERED AT 11:23:49 ON 17 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'PROMT' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Gale Group. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:23:49 ON 17 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'PHIN' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

FILE 'CANCERLIT' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'EMBASE' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'TOXLINE' ENTERED AT 11:23:49 ON 17 MAY 2001

FILE 'SCISEARCH' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'ADISINSIGHT' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 Adis International Ltd. (ADIS)

FILE 'DRUGNL' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 IMSWORLD Publications Ltd

FILE 'DRUGUPDATES' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 IMSWORLD Publications Ltd

FILE 'PHAR' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

FILE 'WPIDS' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DRUGU' ENTERED AT 11:23:49 ON 17 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'PASCAL' ENTERED AT 11:23:49 ON 17 MAY 2001
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2001 INIST-CNRS. All rights reserved.

=> s l9
   7 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
  14 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
L10   51 L9

=> dup rem l10
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, DRUGUPDATES, PHAR'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L10
L11   45 DUP REM L10 (6 DUPLICATES REMOVED)

=> d ibib abs 1-10

L11 ANSWER 1 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2001:3608 PHIN
DOCUMENT NUMBER: C00696126

DATA ENTRY DATE: 15 Jan 2001
TITLE: Breakthrough products enter the US market
SOURCE: Clinica (2001) No. 941 Review-Issue 2000 p33
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 2 OF 45 USPATFULL
ACCESSION NUMBER: 2001:21079 USPATFULL
TITLE: Scanning laser ophthalmoscope for selective therapeutic laser
INVENTOR(S): Van de Velde, Frans J., Boston, MA, United States
PATENT ASSIGNEE(S): Van de Velde, Jozek F., Oosterzele, Belgium (non-U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 6186628	20010213
APPLICATION INFO.:	US 1999-431680	19991101 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-317098, filed on 23 May 1999, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Manuel, George
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 631
AB A combination of a scanning laser ophthalmoscope and external laser sources (52) is used for microphotocoagulation and photodynamic therapy, two examples of selective therapeutic laser. A linkage device incorporating a beamsplitter (56) and collimator-telescope (60) is adjusted to align the pivot point (16) of the scanning lasers (38, 40) and external laser source (52). A similar pivot point minimizes wavefront aberrations, enables precise focusing and registration of the therapeutic laser beam (52) on the retina without the risk of vignetting. One confocal detection pathway of the scanning laser ophthalmoscope images the retina. A second and synchronized detection pathway with a different barrier filter (48) is needed to draw the position and extent of the therapeutic laser spot on the retinal image, as an overlay (64). Advanced spatial modulation increases the selectivity of the therapeutic laser. In microphotocoagulation, an adaptive optics lens (318) is attached to the scanning laser ophthalmoscope, in proximity of the eye. It corrects the higher order optical aberrations of the eye optics, resulting in smaller and better focused applications. In photodynamic therapy, a spatial modulator (420) is placed within the collimator-telescope (60) of the therapeutic laser beam (52), customizing its shape as needed. A similar effect can be obtained by modulating a scanning laser source (38) of appropriate wavelength for photodynamic therapy.

L11 ANSWER 3 OF 45 USPATFULL
ACCESSION NUMBER: 2001:14260 USPATFULL
TITLE: Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
INVENTOR(S): Granville, David J., Vancouver, Canada
Levy, Julia G., Vancouver, Canada

	Hunt, David W. C., Vancouver, Canada	
PATENT ASSIGNEE(S):	QLT Inc., Victoria, Canada (non-U.S. corporation)	
	University of British Columbia, Vancouver, Canada (non-U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 6180402	20010130
APPLICATION INFO.:	US 1996-754491	19961120 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Saucier, Sandra E.	
LEGAL REPRESENTATIVE:	Morrison & Foerster, LLP	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1095	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition and method for inhibiting apoptosis, or decreasing the rate or extent of apoptosis, in target cells. The method comprises the step of the step of contacting the target cells with an apoptosis-regulating amount of at least one cysteine or serine protease inhibitor that:

a. inhibits the conversion of the pro-enzyme form of CPP32 to its enzymatically-active form;

b. blocks the proteolytic action of activated CPP32 against its cellular substrates; or

c. both.

The method is particularly applicable to ameliorating the side effects of, or enhancing the selectivity, of photodynamic therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:	2001:265274 CAPLUS
DOCUMENT NUMBER:	134:262933
TITLE:	Significance of dosimetry in photodynamic therapy of injured arteries
INVENTOR(S):	Lamuraglia, Glenn Michael
PATENT ASSIGNEE(S):	The General Hospital Corporation Doing Business as Massachusetts General Hos, USA
SOURCE:	PCT Int. Appl., 39 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024825	A2	20010412	WO 2000-US27140	20001002

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:	US 1999-157325	P	19991001
	US 1999-157409	P	19991001

AB Photodynamic therapy (PDT), the light activation of methylene blue or benzoporphyrin derivs. to produce free-radicals, was shown in vivo to inhibit **intimal hyperplasia** (IH) and **restenosis**. An effective amt. of photosensitizer is delivered to the injured site in vivo and the site is irradiated with sufficient light energy between about 300 and 900 nm such that **restenosis** is modulated. The light source used is a laser and the light energy about 100 J/cm2. The present invention provides an effective clin. approach for PDT treatment which modulates the vascular intervention injury healing response.

L11 ANSWER 5 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 2001:103819 PROMT
TITLE: Letter to the Editor.(request for age-related macular degeneration percentages)(Brief Article)(Letter to the Editor)
AUTHOR(S): Sonnier, William, Jr.
SOURCE: Ophthalmology Times, (1 Aug 2000) Vol. 25, No. 15, pp. 3. ISSN: 0193-032X.
PUBLISHER: Advanstar Communications, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 159
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Reader questions AMD percentages

Subscription: $150.00 per year. Published semimonthly. 7500 Old Oak Blvd., Cleveland, OH 44130.

L11 ANSWER 6 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 2000:468002 PROMT
TITLE: OTHER NEWS TO NOTE.
SOURCE: BIOWORLD Today, (2 Jun 2000) Vol. 11, No. 107.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1701
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Abbott Laboratories, of Abbott Park, Ill., said it submitted a new drug application to market ABT-378/r (lopinavir/ritonavir), its investigational antiretroviral therapy for HIV and AIDS. The company is seeking accelerated approval based on ongoing Phase II/III studies. The regulatory submission in Europe is planned for late June and applications for other markets outside the U.S. will follow throughout the year. Separately, Abbott has sued Boston's Children's Hospital and one of its cancer researchers, Judah Folkman, alleging they falsely took credit for a medical development in treating malignant tumors by telling U.S. patent reviewers about the discovery of tumor-inhibiting properties of a small section of an angiostatin protein known as Kringle 5. According to wire reports, Abbott filed suit in U.S. District Court in Boston and says one of its scientists, Donald Davidson, actually discovered the properties, making Abbott the rightful owner of the patent.

Subscription: $1350.00 per year. Published daily (5 times a week).

L11 ANSWER 7 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2000:5549 PHIN
DOCUMENT NUMBER: S00656918
DATA ENTRY DATE: 16 Feb 2000
TITLE: Preventive products reap most rewards it could easily become the world's best-selling drug.
SOURCE: Scrip (2000) No. 2514 Review-Issue 1999 p65
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 8 OF 45 PHIN COPYRIGHT 2001 PJB

ACCESSION NUMBER: 2000:15210 PHIN
DOCUMENT NUMBER: C00677424
DATA ENTRY DATE: 29 Aug 2000
TITLE: Medicare's changing coverage policy creates uncertainty
SOURCE: Clinica (2000) No. 923 p6
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L11 ANSWER 9 OF 45 USPATFULL
ACCESSION NUMBER: 2000:132994 USPATFULL
TITLE: Apparatus and method to monitor photodynamic therapy (PDT)
INVENTOR(S): Zeng, Haishan, 11786 85B Avenue, Delta, B. C., Canada V4C 2W2
Lui, Harvey, 3415 West 11th Avenue, Vancouver, B. C., Canada V6R 2K1
MacAulay, Calum, 5791 Prince Albert Street, Vancouver, B. C., Canada V5W 3E1
Palcic, Branko, 3758 Quesnel Drive, Vancouver, B. C., Canada V6L 2W8
McLean, David I., 1246 West 26th Avenue, Vancouver, B. C., Canada V6H 2A9

	NUMBER	DATE
PATENT INFORMATION:	US 6128525	20001003
APPLICATION INFO.:	US 1997-901999	19970729 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lateef, Marvin M.
ASSISTANT EXAMINER: Imam, Ali M.
LEGAL REPRESENTATIVE: Fulwider Patton Lee & Utecht, LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 454

AB A method and apparatus for controlling the dosimetry of a photodynamic therapy that involves exposing a site to be treated to treatment light in order to generate toxic products at the site and other photoproducts.

Often a photosensitizer drug is administered to the patient prior to treatment or the therapy relies on the presence of endogenous photosensitizers. The method comprises the steps of selecting a photoproduct having an identifying characteristic, which can be a fluorescence peak, and monitoring the photoproduct using the identifying

characteristic (e.g. fluorescence) to determine the level of the photoproduct being generated. The photodynamic therapy is then terminated when the photoproduct being monitored reaches a predetermined level. The method allows for safe treatment of a site using photodynamic therapy and ensures that overexposure to treatment light leading to damage of normal tissue or underexposure leading to ineffective treatment of the lesion does not occur. Apparatus for automatically carrying out the method is also provided.

L11 ANSWER 10 OF 45 USPATFULL

ACCESSION NUMBER:	2000:121505 USPATFULL	
TITLE:	Model and method for angiogenesis inhibition	
INVENTOR(S):	Margaron, Philippe Maria Clotaire, Burnaby, Canada Leong, Simon, Burnaby, Canada Levy, Julia G., Vancouver, Canada Richter, Anna M., Vancouver, Canada	
PATENT ASSIGNEE(S):	QLT, Inc., Japan (non-U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 6117862	20000912
APPLICATION INFO.:	US 1998-169735	19981009 (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jones, Dwayne C.	
LEGAL REPRESENTATIVE:	Morrison & Foerster	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	488	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method to inhibit the formation of neovasculature while maintaining viability of the underlying tissue by subjecting a subject in which angiogenesis is to be inhibited to sublethal photodynamic therapy. The invention also provides a model for assessing sublethal PDT protocols to inhibit angiogenesis in particular target tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 11-20

L11 ANSWER 11 OF 45 USPATFULL

AN 2000:109830 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Port Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., North Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6107325 20000822
AI US 1998-80666 19980518 (9)
RLI Continuation-in-part of Ser. No. US 1997-856921, filed on 16 May 1997 which is a continuation-in-part of Ser. No. US 1995-374158, filed on 17

Jan 1995, now patented, Pat. No. US 5789433
DT Utility
LN.CNT 1032
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [7]
ICM: A01N043-38
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 45 USPATFULL
AN 2000:102323 USPATFULL
TI Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
IN Levy, Julia G., Vancouver, Canada
North, Janice, Vancouver, Canada
PA QLT Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6100290 20000808
AI US 1998-152993 19980914 (9)
RLI Continuation of Ser. No. US 1994-309509, filed on 22 Sep 1994, now patented, Pat. No. US 5807881, issued on 15 Sep 1998 which is a continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992, now patented, Pat. No. US 5776966, issued on 7 Jul 1998
DT Utility
LN.CNT 967
INCL INCLM: 514/410.000
INCLS: 514/885.000; 514/908.000; 604/004.000; 604/005.000
NCL NCLM: 514/410.000
NCLS: 514/885.000; 514/908.000; 604/004.010
IC [7]
ICM: A61K031-40
EXF 514/410; 514/885; 514/908; 604/4; 604/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 45 USPATFULL
AN 2000:98460 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Port Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Canada (non-U.S. corporation)
The University of British Columbia, Canada (non-U.S. corporation)
PI US 6096776 20000801
AI US 1998-164374 19981001 (9)
RLI Continuation-in-part of Ser. No. US 1997-856921, filed on 16 May 1997, now patented, Pat. No. US 6008241 which is a continuation-in-part of Ser. No. US 1995-374158, filed on 17 Jan 1995, now patented, Pat. No. US
5789433
DT Utility
LN.CNT 607
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [7]
ICM: A61K031-40
EXF 514/410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 45 USPATFULL
AN 2000:80885 USPATFULL
TI Taxanes
IN Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Webb, Nigel L., Bryn Mawr, PA, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 6080877 20000627
AI US 1997-868476 19970603 (8)
RLI Continuation of Ser. No. US 1996-651429, filed on 22 May 1996, now abandoned
DT Utility
LN.CNT 1034
INCL INCLM: 549/510.000
INCLS: 549/511.000; 514/449.000
NCL NCLM: 549/510.000
NCLS: 549/511.000
IC [7]
ICM: C07D305-14
ICS: A61K031-335
EXF 549/510; 549/511; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 45 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-594142 [56] WPIDS
DNC C2000-177376
TI Enhancing destruction of target cells such as smooth muscle cells or tumor
cells for cancer therapy, involves using photodynamic therapy in combination with apoptosis-inducing factors.
DC B02 B04
IN CARTHY, C M; GRANVILLE, D J; HUNT, D W C
PA (QLTP-N) QLT PHOTOTHERAPEUTICS INC
CYC 90
PI WO 2000051638 A1 20000908 (200056)* EN 64p A61K041-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000027899 A 20000921 (200065) A61K041-00
ADT WO 2000051638 A1 WO 2000-CA200 20000225; AU 2000027899 A AU 2000-27899 20000225
FDT AU 2000027899 A Based on WO 200051638
PRAI US 1999-121770 19990226
IC ICM A61K041-00

L11 ANSWER 16 OF 45 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
AN 2000437509 EMBASE
TI [Limited macular translocation].
BEGRENZTE TRANSLOKATION DER MAKULA BEI SUBFOVEALER CHOROIDALER NEOVASKULARISATION.
AU Wiedemann P.; Faude F.; Jochmann C.; Sterker I.; Wolf S.; Zeumer C.
CS P. Wiedemann, Klinik Poliklinik fur Augenheilkunde, Liebigstrasse 10-14, D-04103 Leipzig, Germany
SO Spektrum der Augenheilkunde, (2000) 14/5 (254-258).

Refs: 18
ISSN: 0930-4282 CODEN: SPAUET
CY Austria
DT Journal; Article
FS 012 Ophthalmology
LA German
SL English; German

L11 ANSWER 17 OF 45 MEDLINE DUPLICATE 1
AN 2001048490 MEDLINE
DN 20386242 PubMed ID: 10933111
TI Benzoporphyrin derivative monacid ring A (**Verteporfin**) alone has no inhibitory effect on **intimal hyperplasia**: in vitro and in vivo results.
AU Turnbull R G; Chen J C; Labow R S; Margaron P; Hsiang Y N
CS University of British Columbia, Vancouver, Canada.
SO JOURNAL OF INVESTIGATIVE SURGERY, (2000 May-Jun) 13 (3) 153-9.
Journal code: AZA. ISSN: 0894-1939.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered PubMed: 20001121
Entered Medline: 20001214

L11 ANSWER 18 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1999:208043 PROMT
TITLE: Best PIPELINES.
AUTHOR(S): Engel, Styli
SOURCE: Med Ad News, (March 1999) Vol. 18, No. 3, pp. 1(1).
ISSN: 0745-0907.
PUBLISHER: Engel Communications, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 41331
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 19 OF 45 PHIN COPYRIGHT 2001 PJB

AN 1999:3225 PHIN
DN S00609484
DED 29 Jan 1999
TI Pharmacia and Upjohn ups investment in Miravant AMD (age-related macular degeneration) drug
SO Scrip (1999) No. 2407 p10
DT Newsletter
FS FULL

L11 ANSWER 20 OF 45 PHIN COPYRIGHT 2001 PJB

AN 2000:244 PHIN
DN S00646196
DED 3 Dec 1999
TI Novartis acquires Destiny's PDT (photodynamic therapy)
SO Scrip (1999) No. 2495 p8
DT Newsletter

FS FULL

=> d 21-30

L11 ANSWER 21 OF 45 USPATFULL
AN 1999:170633 USPATFULL
TI Green porphyrins as immunomodulators
IN Chan, Agnes H., Fort Moody, Canada
Hunt, David W. C., White Rock, Canada
Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
Richter, Anna M., Vancouver, Canada
Simkin, Guillermo O., North Vancouver, Canada
PA QLT PhotoTherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 6008241 19991228
AI US 1997-856921 19970516 (8)
RLI Continuation-in-part of Ser. No. US 1995-374158, filed on 17 Jan 1995, now patented, Pat. No. US 5789433
DT Utility
LN.CNT 966
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [6]
ICM: A61K031-40
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 45 USPATFULL
AN 1999:110319 USPATFULL
TI Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
IN Cincotta, Anthony H., Charlestown, MA, United States
Cincotta, Louis, Andover, MA, United States
Hasan, Tayyaba, Arlington, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
Rowland Institute for Science, Cambridge, MA, United States (U.S. corporation)
PI US 5952329 19990914
AI US 1997-787665 19970123 (8)
DT Utility
LN.CNT 707
INCL INCLM: 514/224.500
INCLS: 514/410.000
NCL NCLM: 514/224.500
NCLS: 514/410.000
IC [6]
ICM: A61K031-54
ICS: A61K031-40
EXF 514/224.5; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 45 USPATFULL
AN 1999:99682 USPATFULL
TI Photodynamic therapy for the treatment of osteoarthritis
IN Trauner, Kenneth, Sacramento, CA, United States
Hasan, Tayyaba, Arlington, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

PI US 5942534 19990824
AI US 1997-948623 19971010 (8)
PRAI US 1996-28198 19961010 (60)
DT Utility
LN.CNT 864
INCL INCLM: 514/410.000
INCLS: 514/561.000; 514/429.000; 514/825.000
NCL NCLM: 514/410.000
NCLS: 514/429.000; 514/561.000; 514/825.000
IC [6]
ICM: A01N043-38
EXF 514/561; 514/825; 514/410; 514/429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 45 USPATFULL
AN 1999:75671 USPATFULL
TI Taxane compounds and compositions
IN Bradley, Matthews O., Laytonville, MD, United States
Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5919815 19990706
AI US 1996-653951 19960522 (8)
DT Utility
LN.CNT 940
INCL INCLM: 514/449.000
INCLS: 549/510.000
NCL NCLM: 514/449.000
NCLS: 549/510.000
IC [6]
ICM: A61K031-335
EXF 549/510; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 45 USPATFULL
AN 1999:33242 USPATFULL
TI Method to prevent transplant rejection
IN Levy, Julia G., Vancouver, Canada
Obochi, Modestus O. K., Vancouver, Canada
PA QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5882328 19990316
AI US 1996-759318 19961202 (8)
RLI Continuation-in-part of Ser. No. US 1995-371707, filed on 13 Jan 1995, now abandoned
DT Utility
LN.CNT 1461
INCL INCLM: 604/020.000
INCLS: 604/049.000; 424/810.000; 128/898.000
NCL NCLM: 604/020.000
NCLS: 128/898.000; 424/810.000; 604/500.000
IC [6]
ICM: A61N001-30
ICS: I61M031-00
EXF 604/19; 604/20; 604/48; 604/49; 514/885; 530/388.7; 530/388.73; 530/388.75; 530/388.8; 530/388.85; 424/810; 424/140.1; 128/898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1999:682214 CAPLUS

DN 132:10414
TI Significance of dosimetry in photodynamic therapy of injured arteries: classification of biological responses
AU Adili, Farzin; Van Eps, Randolph G. Statius; LaMuraglia, Glenn M.
CS Division of Vascular Surgery and the Wellman Laboratories of Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, 02114, USA
SO Photochem. Photobiol. (1999), 70(4), 663-668
CODEN: PHCBAP; ISSN: 0031-8655
PB American Society for Photobiology
DT Journal
LA English
RE.CNT 29
RE
(4) Dubbelman, T; Photodynamic Therapy Basic Principles and Clinical Applications 1992, P37 CAPLUS
(5) Eton, D; Arch Surg 1995, V130, P1098 CAPLUS
(8) Grant, W; Br J Cancer 1994, V70, P72 CAPLUS
(9) Grant, W; Laryngoscope 1995, V105, P867 CAPLUS
(10) Henderson, B; Photochem Photobiol 1992, V55, P145 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1998:222577 PROMT
TITLE: ATTENTION BUSINESS EDITORS:
SOURCE: PR Newswire, (30 Apr 1998) pp. 0430VA002.
LANGUAGE: English
WORD COUNT: 1352
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 28 OF 45 PROMT COPYRIGHT 2001 Gale Group

ACCESSION NUMBER: 1998:222488 PROMT
TITLE: QLT Announces Strategic Alliance With Bard To Develop System For **Restenosis**
SOURCE: PR Newswire, (30 Apr 1998) pp. 0430LNTH001.
LANGUAGE: English
WORD COUNT: 765
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L11 ANSWER 29 OF 45 USPATFULL
AN 1998:138935 USPATFULL
TI Methods to treat arterial plaque
IN Kelly, Barbara, Vancouver, Canada
Levy, Julia, Vancouver, Canada
Margaron, Philippe Maria Clotaire, Vancouver, Canada
PA QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5834503 19981110
AI US 1996-663890 19960614 (8)
DT Utility
LN.CNT 671
INCL INCLM: 514/410.000
INCLS: 514/824.000
NCL NCLM: 514/410.000
NCLS: 514/824.000
IC [6]
ICM: A61K031-40
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 45 USPATFULL
AN 1998:111961 USPATFULL
TI Method for selectively reducing activated leukocyte cell population
IN Leong, Simon, Vancouver, Canada
Chan, Agnes How-Ching, Port Moody, Canada
Hunt, David William Carey, White Rock, Canada
Levy, Julia, Vancouver, Canada
Renke, Martin, Burnaby, Canada
PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5807881 19980915
AI US 1994-309509 19940922 (8)
RLI Continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992
DT Utility
LN.CNT 1016
INCL INCLM: 514/410.000
INCLS: 604/004.000; 604/005.000; 514/885.000; 514/908.000
NCL NCLM: 514/410.000
NCLS: 514/885.000; 514/908.000; 604/006.080
IC [6]
ICM: A61K031-40
EXF 514/410; 604/4; 604/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 31-45

L11 ANSWER 31 OF 45 USPATFULL
AN 1998:98932 USPATFULL
TI DHA-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5795909 19980818
AI US 1996-651312 19960522 (8)
DT Utility
LN.CNT 2451
INCL INCLM: 514/449.000
INCLS: 514/549.000
NCL NCLM: 514/449.000
NCLS: 514/549.000
IC [6]
ICM: A61K031-335
ICS: A61K031-22
EXF 514/449; 514/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 32 OF 45 MEDLINE DUPLICATE 2
AN 1999103397 MEDLINE
DN 99103397 PubMed ID: 9888322
TI Photodynamic therapy with local photosensitizer delivery inhibits experimental **intimal hyperplasia.**
AU Adili F; Statius van Eps R G; Flotte T J; LaMuraglia G M
CS Division of Vascular Surgery, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.

NC HL02583 (NHLBI)
SO LASERS IN SURGERY AND MEDICINE, (1998) 23 (5) 263-73.
Journal code: L1X; 8007168. ISSN: 0196-8092.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199903
ED Entered STN: 19990402
Last Updated on STN: 19990402
Entered Medline: 19990322

L11 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1997:319963 CAPLUS
DN 126:327524
TI Delivery of benzoporphyrin derivative, a photosensitizer, into atherosclerotic plaque of Watanabe heritable hyperlipidemic rabbits and balloon-injured New Zealand rabbits
AU Allison, B. A.; Crespo, M. T.; Jain, A. K.; Richter, A. M.; Hsiang, Y. N.;
Levy, J. G.
CS Department of Surgery, University of British Columbia, Vancouver, BC, V6T 2B5, Can.
SO Photochem. Photobiol. (1997), 65(5), 877-883
CODEN: PHCBAP; ISSN: 0031-8655
PB American Society for Photobiology
DT Journal
LA English

L11 ANSWER 34 OF 45 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1996-48628 DRUGU P
TI Tin ethyl etiopurpurin significantly inhibits vascular smooth muscle cell
proliferation in vivo.
AU Coats W D Jr; Currier J W; Mejias Y; Narciso H L; Faxon D P
CS Univ.Southern-California
LO Los Angeles, Cal., USA
SO Biochem.Cell Biol. (74, No. 3, 325-31, 1996) 4 Fig. 23 Ref.
CODEN: BCBIEQ ISSN: 0829-8211
AV The Department of Medicine, Division of Cardiology, University of Southern California School of Medicine, 1355 San Pablo Street, Los Angeles, CA 90033, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L11 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1996:434564 CAPLUS
DN 125:136570
TI Effects of benzoporphyrin derivative monoacid on balloon injured arteries in a swine model of **restenosis**
AU Vincent, G. Michael; Fox, Jolene; Johnson, Suzanne; Maragon, Phillipe
CS LDS Hospital, Salt Lake City, UT, USA
SO Proc. SPIE-Int. Soc. Opt. Eng. (1996), 2671(Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VI), 72-77
CODEN: PSISDG; ISSN: 0277-786X
DT Journal
LA English

L11 ANSWER 36 OF 45 PASCAL COPYRIGHT 2001 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1997-0009011 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN Effects of benzoporphyrin derivative monoacid on balloon injured arteries
in a swine model of **restenosis** : Diagnostic and therapeutic cardiovascular intervention VI
Lasers in surgery : advanced characterization, therapeutics, and systems VI : San Jose CA, 27-30 Janaury 1996
AU VINCENT G. M.; FOX J.; JOHNSON S.; MARAGON P.
ANDERSON R. Rox (ed.)
CS LDS Hospital/University of Utah School of Medicine, Salt Lake City, UT, United States; QLT Phototherapeutics Inc., Vancouver, B.C., Canada
International Society for Optical Engineering, Bellingham WA, United States (patr.)
SO SPIE proceedings series, (1996), 2671, 72-77, 18 refs.
Conference: 6 Lasers in surgery : advanced characterization, therapeutics, and systems. Conference, San Jose CA (United States), 27 Jan 1996
ISSN: 1017-2653
DT Journal; Conference
BL Analytic
CY United States
LA English
AV INIST-21760, 354000064004780100

L11 ANSWER 37 OF 45 USPATFULL
AN 95:50186 USPATFULL
TI Method to inhibit **restenosis**
IN Vincent, G. Michael, Salt Lake City, UT, United States
Logan, Patricia M., Vancouver, Canada
PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5422362 19950606
AI US 1993-99210 19930729 (8)
DT Utility
LN.CNT 618
INCL INCLM: 514/410.000
NCL NCLM: 514/410.000
IC [6]
ICM: A61K031-40
EXF 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1995:446841 CAPLUS
DN 122:178400
TI Green porphyrins for inhibition of **restenosis**
IN Vincent, G. Michael; Logan, Patricia M.
PA Quadra Logic Technologies, Inc., Can.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503797	A1	19950209	WO 1994-US8200	19940720
	W: AU, CA, CN, CZ, FI, JP, KR, NO, NZ, PL, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

	US 5422362	A	19950606	US 1993-99210	19930729
	CA 2168043	AA	19950209	CA 1994-2168043	19940720
	AU 9474017	A1	19950228	AU 1994-74017	19940720
	AU 684301	B2	19971211		
	EP 711161	A1	19960515	EP 1994-923992	19940720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1127991	A	19960731	CN 1994-192924	19940720
	JP 09503998	T2	19970422	JP 1994-505883	19940720
	ZA 9405657	A	19960129	ZA 1994-5657	19940729
	NO 9600339	A	19960326	NO 1996-339	19960126
PRAI	US 1993-99210		19930729		
	WO 1994-US8200		19940720		

OS MARPAT 122:178400

L11 ANSWER 39 OF 45 SCISEARCH COPYRIGHT 2001 ISI (R)
AN 95:746273 SCISEARCH
GA The Genuine Article (R) Number: TB169
TI ASSESSMENT OF THE CYTOTOXICITY OF THE PHOTOSENSITIZING DRUG BPD **VERTEPORFIN** USING HUMAN VASCULAR SMOOTH-MUSCLE CELLS IN CULTURE
AU LABOW R S (Reprint); HIGGINSON L A J; IRVINE J; KEANEY M; MASTERS R G; MARQUIS J F; MEEK E; MUSSIVAND T; WALLEY V M; LOGAN P; CHALY N; LOWRY M
CS UNIV OTTAWA, OTTAWA CIVIC HOSP, INST HEART, DIV CARDIOVASC DEVICES, 1053 CARLING AVE, OTTAWA, ON K1Y 4E9, CANADA (Reprint); QUADRA LOG TECHNOL, VANCOUVER, BC, CANADA; CARLETON UNIV, DEPT BIOL, OTTAWA, ON K1S 5B6, CANADA
CYA CANADA
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (NOV 1995) Vol. 26, No. 5, pp. 729-736.
ISSN: 0160-2446.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 36
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L11 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2001 ACS
AN 1995:702859 CAPLUS
DN 123:164182
TI Local delivery of photosensitizing drugs in arteries: a novel approach to photodynamic therapy for the prevention of **intimal hyperplasia**
AU Adili, Farzin; van Eps, Randolph G. S.; LaMuraglia, Glenn M.
CS Harvard Medical School, Massachusetts General Hospital, Boston, MA, 02114, USA
SO Proc. SPIE-Int. Soc. Opt. Eng. (1995), 2395, 402-8
CODEN: PSISDG; ISSN: 0277-786X
DT Journal
LA English

L11 ANSWER 41 OF 45 DRUGNL COPYRIGHT 2001 IMSWORLD

ACCESSION NUMBER: 94:1182 DRUGNL
TITLE: **Verteporfin** Effective in Psoriasis Clinicals
SOURCE: R&D Focus Drug News (31 Oct 1994).
WORD COUNT: 207

L11 ANSWER 42 OF 45 MEDLINE DUPLICATE 3
AN 95084221 MEDLINE

DN 95084221 PubMed ID: 7992105
TI Photosensitizers in photodynamic therapy.
AU Levy J G
CS Quadra Logic Technologies, Inc, Vancouver, British Columbia, Canada.
SO SEMINARS IN ONCOLOGY, (1994 Dec) 21 (6 Suppl 15) 4-10.
Journal code: UN5; 0420432. ISSN: 0093-7754.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199501
ED Entered STN: 19950124
Last Updated on STN: 19980206
Entered Medline: 19950112

L11 ANSWER 43 OF 45 ADISINSIGHT COPYRIGHT 2001 (ADIS)
ACCESSION NUMBER: 1998:5242 ADISINSIGHT
SOURCE: Adis R&D Insight
DOCUMENT NO: 005843
CHANGE DATE: May 9, 2001
GENERIC NAME: **Verteporfin**
SYNONYM: BPD; BPD-MA; Benzoporphyrin derivative monoacid ring A; CL 315555; CL 315585; CL 318952; Everteporfine;

Visudyne
CHEMICAL NAME: 50:50 mixture of: (+-)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine- 9,13-dipropionic acid, 3,4,9-trimethyl ester and (+-)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester.
MOLECULAR FORMULA: C41 H42 N4 O8
CAS REGISTRY NO.: **129497-78-5**
STRUCTURE:

CM 1

Relative stereochemistry.
Double bond geometry unknown.



CM 2

H_3C-OH

EPHMRA ATC CODE: C6A Other Cardiovascular Products; D5A Topical Antipsoriasis and Similar Products; L1X9 All other cytostatics; L3 Immunostimulating Agents; M1A Anti-Rheumatics, Non-Steroidal; S1X Other Ophthalmologicals

WHO ATC CODE: C Cardiovascular System; D05A-X Other antipsoriatics for topical use; L01X Other Antineoplastic Agents; L03 Immunostimulants; M01A Antiinflammatory and Antirheumatic Products, Non-steroids; S01X Other Ophthalmologicals

HIGHEST DEV. PHASE: Launched

COMPANY INFORMATION

ORIGINATOR: Nonindustrial source (Canada)
PARENT: Nonindustrial source
LICENSEE: Medtronic AVE; Novartis Ophthalmics; QLT
OTHER: Coherent; Nippon Fine Chemical; Parkedale Pharmaceuticals; Raylo

WORD COUNT: 2819

L11 ANSWER 44 OF 45 DRUGUPDATES COPYRIGHT 2001 IMSWORLD

ACCESSION NUMBER: 93:3852 DRUGUPDATES
SOURCE: R&D Focus, (2 Apr 2001)
GENERIC NAME: **verteporfin**; benzoporphyrin derivative; BPD-MA
REFERENCE: USAN
LABORATORY NAME: CL 318952; BPDR
TRADE NAME: VISUDYNE
CHEMICAL NAME: trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetr amethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester
CAS REGISTRY NO.: **129497-78-5**
STRUCTURE:

CM 1

Relative stereochemistry.
Double bond geometry unknown.



CM 2

H_3C-OH

DERIVATIVE(S): **129497-78-5verteporfin**
121987-00-6replaced by 129497-78-5
129162-83-0replaced by 129497-78-5
136415-38-8replaced by 129497-78-5

CLASSIFICATION: L1X Other Cytostatics; D5 Antipsoriasis Products; M1A Antirheumatic Non-Steroidal; S1 Ophthalmologicals

HIGHEST DEV. PHASE: Marketed (80)

COMPANY INFORMATION:

Type	Company	Nationality	Region
Originator	British Columbia University	Canada	
Licensee : licensor	QLT	Canada	
Sub-licensee	Beaufour Ipsen	France	cancer
Sub-licensee	Novartis	Switzerland	Worldwide
Assignee	British Columbia University		
Assignee	Quadra Logic		

L11 ANSWER 45 OF 45 PHAR COPYRIGHT 2001 PJB
AN 1589 PHAR
DN 013031
CN **verteporfin**
CN BPD
CN BPD-MA

CN benzoporphyrin derivative
CN Chlorin
CN CL-315555+CL-315585
CN CL-318952
CN Visudyne
CN 23H,25H-Benzo(b)porphine-9,13-dipropanoic acid,18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl -,monomethyl ester, trans- (CAS)
RN **129497-78-5**
STA Active

CO

Type	Company Name (Country)	Development Status
Originator	QLT (Canada)	Launched
Licensee	Novartis Ophthalmics (Switzerland)	Launched
Licensee	Sanofi-Synthelabo (France)	Phase II Clinical Trial
Licensee	Beaufour-Ipsen (France)	Phase II Clinical Trial

SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK
TX QLT has developed **verteporfin**, a light-activated benzoporphyrin derivative (BPD), as a photodynamic therapy (licensed from the University of British Columbia, Canada). A photochemical dye is injected iv and localizes to areas of new blood vessels. Non-thermal laser irradiation is then used to produce vascular occlusion (Br J Ophthalmol, 1998, 82, 472).

Marketing
It is launched in Switzerland (1999), Germany, the UK and the US (2000) (Chem Brit, Apr, 2000, 6; Scrip Daily Online, 9 Nov 2000, S00686884) for the treatment of wet age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization (CNV) (Press releases, Ciba Vision, 16 Dec 1999 and QLT, 12 Apr 2000). It is registered in 31 countries (as of Feb 2001) including Australia, Canada and the EU for the treatment of AMD (Press releases, Ciba Vision, 1 Jun and 3 Oct 2000 and Novartis Ophthalmics, 5 Feb 2001). It is also approved in the EU for the treatment of CNV secondary to pathologic myopia (Press release, Novartis Ophthalmics, 23 Mar 2001). It is awaiting registration in Argentina, Brazil, Iceland, India, New Zealand (accelerated review status) and Norway (Scrip Daily Online, 14 Feb 2000; Press releases, Ciba Vision, 18 Aug and 28 Mar 2000). An agreement has been signed with Novartis Ophthalmics (previously Ciba Vision Ophthalmics) for use in eye diseases, such as AMD, glaucoma and secondary cataracts (preclinical), CNV, intraocular tumours and diabetic retinopathy (Company communications, Ciba Vision, Feb 1995 and QLT, Feb 1995; Scrip, 1995, 2083, 11; Press release, QLT, Mar 1996). A filing for the treatment of eye diseases other than AMD has been submitted to the EMEA by QLT and Novartis Ophthalmics (Press release, Ciba Vision, 3 Oct 2000). A US supplemental filing for pathologic myopia has been granted priority review status (approvable letter received; approval expected in mid-2001) (Company Web Page, Novartis, 16 Jan 2001; Press release, Novartis Ophthalmics, 5 Feb 2001). Sanofi-Synthelabo holds rights to development for cutaneous cancers (Phase II trials) and psoriasis (Scrip, 1996, 2146, 11). It is being developed with

Beaufour-Ipsen for oncology (Company communication, Dec 1997). The Baylor Research Institute, Dallas, TX, the US, has an agreement for use in viral inactivation and blood-borne disease (Press release, QLT, Aug 1993). QLT has reacquired worldwide marketing rights from American Cyanamid (American Home Products) (Press release, QLT, Mar 1994). A licence to Novartis to co-develop and market **verteporfin** for cancer and psoriasis (US and Canadian Phase I/II trials with topical **verteporfin** were carried out) has been discontinued (Scrip, 1994, 1934, 9 and 1981, 23; Press release, QLT, Nov 1994; Direct communication, Novartis, 13 Mar 1999).

Clinical

In a 24mth, pivotal, randomized, double-blind study (TAP) in 609 AMD patients at 22 centres in N America and Europe, vision was stable or improved at 12mth follow-up, in 67% of patients cf 39% of placebo recipients. **Verteporfin**-treated patients were 72% more likely to retain their vision cf placebo. Withdrawal due to adverse events was <3% (Press release, Ciba Vision, 11 Aug 1999). At 24mth follow-up, of the 242 patients with classic CNV, 59.1% of those treated lost <3 lines of vision cf 31.3% on placebo, and 13% of **verteporfin**-treated patients experienced an improvement in vision. Average number of treatments required decreased from 3.4 to 2.1 in the 2nd 12mth. It was safe and well tolerated. An open-label 24mth study (TAP extension) is underway. In a multicentre, randomized, placebo-controlled Phase IIIb study (VIP) in 120 patients with CNV due to pathologic myopia, 86.4% of **verteporfin** -treated patients lost <3 lines of vision cf 66.7% on placebo, and treated patients showed significant improvements in contrast sensitivity, lesion size and amount of leakage. In an additional multicentre, randomized, placebo-controlled Phase IIIb trial in 339 AMD patients with a different pattern of CNV, not eligible for the TAP trial, **verteporfin** did not produce significant benefit, with 49.3% of treated patients losing <3 lines of vision cf 45.6% on placebo (Press release, Ciba Vision and QLT, 28 Mar 2000). In a Phase IIIb clinical trial in AMD patients with occult subfoveal CNS, **verteporfin** was efficacious (Scrip Daily Online, 8 Feb 2001, S00696576). It was in Phase III trials as an immunosuppressant (bone marrow purging) and in Phase I/II as an immunological anti-HIV agent (Company communications, QLT, Feb 1993 and Dec 1995). In a Phase II study in 54 patients with non-melanoma skin cancer in the US and Canada, **verteporfin** produced CRs in 98% of tumours 6mth after treatment at the highest light dose (Press release, QLT, 31 Oct 2000). In case studies of patients with macular degeneration, drug treatment resulted in stabilization of vision and reduction in vision distortion (Company communication, QLT, Nov 1995). In 61 patients with wet AMD, partial or complete closure of the diseased blood vessels was demonstrated in all lesions post-treatment. In the majority of patients, selective closure was achieved and blood vessel leakage was significantly reduced, while mean visual acuity remained stable over a 3mth follow-up period (Press release, QLT, Apr 1996). In a Phase I trial in 19 psoriasis patients, 5 had >35% reduction in total PASI (Psoriasis Area and Severity Index) scores after 9wk, with 2 patients experiencing 77 and 61% reduction, respectively. The most common side-effect (21%) was mild-to-moderate pruritus. BPD is in Phase I trials for gynaecological infections (Company communications, QLT, Jan 1993 and Mar 1995).

Preclinical

Verteporfin is also under investigation for atherosclerosis, multiple sclerosis (both preclinical),

restenosis, cervical dysplasia and in Japan for AMD (Company communications, QLT, Jan 1993 and Mar 1995; Scrip, 1996, 2146, 11). Updated by AW on 23/3/2001.

Additional ReferencesArch Opthalmol, 1999, 117, 1329.

DSTA World: Launched
Argentina: Pre-registration
Australia: Registered
Austria: Registered
Belgium: Registered
Brazil: Pre-registration
Canada: Registered
Denmark: Registered
France: Registered
Germany, Federal Republic of: Launched 2000
Greece: Registered
Ireland: Registered
Italy: Registered
Japan: Preclinical
Netherlands: Registered
Portugal: Registered
Spain: Registered
Sweden: Registered
Switzerland: Launched 1999
United Kingdom: Launched 2000
United States: Launched 2000

CC S1Z Ophthalmological
I5 Immunosuppressant
I1A Immunostimulant, anti-AIDS
K5A Radio-chemosensitizer
K6Z Anticancer, other
D5A Antipsoriasis

CT Indication: Macular degeneration; Transplant rejection, bone marrow; Infection, HIV/AIDS; Cancer, skin, general; Psoriasis; Infection, gynaecological

ORGM CH-SY (Chemical synthesis, synthetic)

RTE P-IV (Parenteral, intravenous)

RDAT 19911215 RNTE ##Status changed Phase I Clinical Trial
19920315 ##Status changed Phase II Clinical Trial
19930305 ##Status changed Phase III Clinical Trial
19940520 ##Licensee discontinued American Cyanamid
19940617 ##New Licensee Ciba Vision
19940708 ##New Licensee Ciba-Geigy
19950616 ##Change in Licensee Status Ciba Vision Ophthalmics, Phase I Clinical Trial
19950623 ##Change in Licensee Status Ciba Vision, Phase I Clinical Trial
19960426 ##Change in Licensee Status Ciba Vision Ophthalmics, Phase II Clinical Trial
19960816 ##New Licensee Sanofi
19971219 ##New Licensee Beaufour Ipsen
19990319 ##Licensee discontinued Novartis
19990813 ##Registration submission The EU
20000114 ##First registration Switzerland, 19991216
20000421 ##Additional registration The US
20000526 ##First launch NAS, Switzerland, 19991231
20000526 ##Additional launch The US
20000616 ##Additional registration Canada
20000811 ##Additional registration The EU
20000818 ##Additional launch The UK

20001006 ##Additional registration Australia
20001117 ##Additional launch Germany
PHCD RAD-AG; Physiological, Biochemical, Radical formation agonist; Radical formation stimulant; Antineoplastic e.g. rubicins; Radical donator; P-B-RAD-AG.
PHCD P; P-AG; P-B; P-B-AG; P-B-RAD; P-B-RAD-AG; B; B-AG; B-RAD; B-RAD-AG; RAD; RAD-AG.

LN

Therapy (CC)	Pharmacology (PHCD)	Status (DSTC)
S1Z	RAD-AG	L
I5	RAD-AG	C3
I1A	RAD-AG	C2
K5A	RAD-AG	C2
K6Z	RAD-AG	C2
D5A	RAD-AG	C1

NRAT 6:Novelty Rating - Leading Compound
MRAT 3:Market Rating - US$ 2001-5000 million
SRAT 4:Speed Rating - Faster than Average
TRAT 13:Total Rating - Total Rating

CM 1

Relative stereochemistry.
Double bond geometry unknown.



CM 2

H3C—OH

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	127.75	164.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.59	-0.59

FILE 'STNGUIDE' ENTERED AT 11:34:06 ON 17 MAY 2001

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2001 (20010511/UP).